Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Algeta ASA Stories

2014-03-26 16:25:57

LONDON, March 26, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global Radiopharmaceutical Market 2012-2016 TechNavio's analysts forecast the Global Radio Pharmaceutical market to grow at a CAGR of 18.39 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Radio Pharmaceutical market has also been witnessing the increasing demand for radiopharmaceuticals....

2013-05-02 04:21:48

RICHMOND, Calif., May 2, 2013 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in new proprietary bi-functional metal-chelation technology for use in targeted radiopharmaceuticals has announced that Algeta ASA (OSE:ALGETA), a company focused on the development of novel targeted cancer therapeutics, has exercised its option to take an exclusive worldwide licence to Lumiphore's patented Lumi4(®) bi-functional chelator technology and has extended the collaboration to include...

2011-08-23 01:00:00

OSLO, Norway, August 23, 2011 /PRNewswire/ -- Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, today announced that radium-223 chloride has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of castration-resistant (hormone refractory) prostate cancer in patients with bone metastases Andrew Kay, Algeta's President and CEO, said: "The positive results at the pre-planned...

2011-08-23 01:00:00

WAYNE, N.J., Aug. 23, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. today announced that its investigational compound radium-223 chloride, which is exclusively licensed from Algeta ASA, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of castration-resistant (hormone-refractory) prostate cancer in patients with bone metastases. Radium-223 chloride is an investigational agent and is not approved by the FDA, the European...

2011-06-06 02:50:00

OSLO, Norway, June 6, 2011 /PRNewswire-FirstCall/ -- - Trial Stopped Based on Data Results from Pre-Planned Interim Analysis; Patients in Placebo Arm Will Be Offered Treatment with Radium-223 Chloride Algeta ASA (OSE: ALGETA) today announced that the Phase III ALSYMPCA (radium-223 chloride in SYMptomatic Prostate CAncer) trial evaluating the investigational compound radium-223 chloride, which is exclusively licensed by Bayer, in patients with castration-resistant prostate cancer...

2011-06-06 00:00:00

WAYNE, N.J., June 6, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival. Based on a recommendation from the Independent Data...

2010-10-21 07:00:00

RICHMOND, Calif., Oct. 21 /PRNewswire/ -- Lumiphore Inc., a biotechnology leader in new proprietary bifunctional metal-chelation technology for use in high-value imaging, diagnostics, and therapeutics and Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announced that they have signed a global agreement on incorporation of Lumiphore's Lumi4® complexes in Algeta's targeted radiotherapeutics and companion diagnostics. Under the agreement, Algeta has an option to...

2009-12-11 08:04:00

OSLO, December 11 /PRNewswire-FirstCall/ -- Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton. The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study is a double-blind,...

2009-09-03 01:00:00

OSLO, September 3 /PRNewswire-FirstCall/ -- - Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial...

2009-02-03 03:00:00

OSLO, Norway, February 3 /PRNewswire-FirstCall/ -- - ALSYMPCA Study Designed to Evaluate Alpharadin for the Treatment of Bone Metastases in Prostate Cancer Patients Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that it is to enroll US patients into its ALSYMPCA phase III trial evaluating Alpharadin as a new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC). This decision follows a successful end-of-phase II meeting*...